Keywords: amgen, set, decide, cytokinetics, license, drug, developer

Amgen set to decide on Cytokinetics license

Article | 09 March 2009

Print This

US drug developer Cytokinetics has delivered to its partner, Amgen data from Phase I and IIa studies of CK-1827452 that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in